Resources
National strategic action plan for kidney disease
This Action Plan aims to provide a blueprint for transforming kidney disease in Australia over the next 10 ten years with over 30 actions across 3 priority areas designed to address the most pressing needs in kidney disease.
National Strategic Action Plan for Rare Diseases
The National Strategic Action Plan for Rare Diseases outlines principles and actions to bring about the best possible health and wellbeing outcomes for Australians living with a rare disease.
Life Saving Drugs Program – Hereditary tyrosinaemia (type 1) – Medicines review protocol
This final protocol describes the methodology reviewers will follow to assess use of Life Saving Drugs Program medicines for hereditary tyrosinaemia (type 1).
Life Saving Drugs Program – Mucopolysaccharidosis type I (MPS I) – Medicines review protocol
This final protocol describes the methodology reviewers will follow to assess use of Life Saving Drugs Program medicines for MPS I.
Life Saving Drugs Program – Mucopolysaccharidosis type VI (MPS VI) – Medicines review protocol
This final protocol describes the methodology reviewers will follow to assess use of Life Saving Drugs Program medicines for MPS VI.
MRFF snapshot – Cardiovascular Health Mission
This snapshot shows this Mission at a glance. It includes budgets, early funding priorities and grant timelines, as at November 2019. Researchers and other stakeholders can use it to plan for upcoming opportunities and see how the Mission will be established, expanded and embedded over time.
MRFF snapshot – Clinical Trials Activity
This snapshot shows this initiative at a glance. It includes budgets, early funding priorities and grant timelines, as at November 2019. Researchers and other stakeholders can use it to plan for upcoming opportunities and see how the initiative will be established, expanded and embedded over time.
National Strategic Action Plan for Osteoporosis 2019
The National Strategic Action Plan for Osteoporosis 2019 aims to reduce the impact of this condition in Australia. It outlines priority areas and actions to improve the quality of life of Australians living with osteoporosis.
National Strategic Action Plan for Macular Disease
The National Strategic Action Plan for Macular Disease proposes a national response to macular disease across all levels of government in Australia. It recommends action in 4 major areas.
Life Saving Drugs Program – Paroxysmal nocturnal haemoglobinuria – Medicines review protocol
This final protocol describes the methodology reviewers will follow to assess use of Life Saving Drugs Program medicines for paroxysmal nocturnal haemoglobinuria.
Life Saving Drugs Program – Pompe disease – Medicines review protocol
This final protocol describes the methodology reviewers will follow to assess use of Life Saving Drugs Program medicines for Pompe disease.
Life Saving Drugs Program – Mucopolysaccharidosis type II (MPS II) – Medicines review protocol
This final protocol describes the methodology reviewers will follow to assess use of Life Saving Drugs Program medicines for MPS II.
Life Saving Drugs Program – Fabry disease – Medicines review protocol
This final protocol describes the methodology reviewers will follow to assess use of Life Saving Drugs Program medicines for Fabry disease.
Life Saving Drugs Program – Gaucher disease (type 1) – Medicines review protocol
This final protocol describes the methodology reviewers will follow to assess use of enzyme replacement medicines under the Life Saving Drugs Program medicines for Gaucher disease (type 1).
National Strategic Action Plan for Arthritis
The National Strategic Action Plan for Arthritis aims to guide national efforts to address the burden of arthritis.
National Strategic Action Plan for Inflammatory Bowel Disease
The National Strategic Action Plan for Inflammatory Bowel Disease (IBD) provides a path to better care, better quality of life and reduced burden of IBD for the Australian community.
National Strategic Action Plan for Childhood Heart Disease
The National Strategic Action Plan for Childhood Heart Disease (CHD) aims to reduce the impact of this condition in Australia. It outlines priority areas and actions to help people with CHD live longer, healthier and more productive lives.
National Strategic Action Plan for Lung Conditions
The National Strategic Action Plan for Lung Conditions outlines an evidence-based approach to reducing the burden of lung conditions in Australia.
Healthy ageing: developmental research report
We commissioned a market research study into healthy ageing, identifying how we can help encourage Australians to make the most of their later years.
Population-based screening framework
This framework sets out the principles of screening programs for cancer and chronic diseases. It informs decision makers about the key issues to consider when deciding whether to introduce a screening program.
National Action Plan for Endometriosis
This National Action Plan for Endometriosis acknowledges that endometriosis causes a substantial health burden in Australia. It sets goals and objectives to address this burden.
Tackling Indigenous Smoking program – Final evaluation report – July 2018
This report, completed in July 2018, evaluates how effective the Tackling Indigenous Smoking (TIS) program has been and whether it’s on target to achieve its long-term goals.
Procedure guidance for medicines funded through the Life Saving Drugs Program (LSDP)
This guidance document outlines our process and associated timelines to consider medicines seeking funding through the LSDP. It helps sponsors to prepare an application to make an ultra-rare disease medicine available on the LSDP.
Ensuring the future sustainability of the Life Saving Drugs Program
This agreement between the Government and Medicines Australia (MA) facilitates cooperation between them to ensure the future sustainability of the Life Saving Drugs Program.
Newborn Bloodspot Screening – National Policy Framework
The Newborn Bloodspot Screening National Policy Framework guides the national policies needed to support the ongoing success of newborn bloodspot screening in Australia.
Date last updated: